Acrivon Therapeutics Analyst Ratings
Acrivon Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2023 | 455.56% | BMO Capital | $25 → $24 | Maintains | Outperform |
| 10/05/2023 | 455.56% | Maxim Group | → $24 | Initiates Coverage On | → Buy |
| 09/06/2023 | 362.96% | HC Wainwright & Co. | → $20 | Reiterates | Buy → Buy |
| 08/18/2023 | 501.85% | JonesTrading | → $26 | Initiates Coverage On | → Buy |
| 08/11/2023 | 362.96% | HC Wainwright & Co. | $21 → $20 | Reiterates | Buy → Buy |
| 06/02/2023 | 478.7% | Oppenheimer | → $25 | Initiates Coverage On | → Outperform |
| 05/08/2023 | 478.7% | BMO Capital | → $25 | Initiates Coverage On | → Outperform |
| 05/02/2023 | 455.56% | HC Wainwright & Co. | → $24 | Reiterates | → Buy |
| 04/20/2023 | 455.56% | HC Wainwright & Co. | → $24 | Initiates Coverage On | → Buy |
| 12/12/2022 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 12/12/2022 | 293.52% | Jefferies | → $17 | Initiates Coverage On | → Buy |
| 12/12/2022 | 478.7% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/10/2023 | 455.56% | BMO Capital | 25 美元 → 24 美元 | 维护 | 跑赢大盘 |
| 10/05/2023 | 455.56% | Maxim 集团 | → 24 美元 | 启动覆盖范围开启 | → 购买 |
| 09/06/2023 | 362.96% | HC Wainwright & Co. | → 20 美元 | 重申 | 购买 → 购买 |
| 08/18/2023 | 501.85% | JonesTrading | → 26 美元 | 启动覆盖范围开启 | → 购买 |
| 08/11/2023 | 362.96% | HC Wainwright & Co. | 21 美元 → 20 美元 | 重申 | 购买 → 购买 |
| 06/02/2023 | 478.7% | 奥本海默 | → 25 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 05/08/2023 | 478.7% | BMO Capital | → 25 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 05/02/2023 | 455.56% | HC Wainwright & Co. | → 24 美元 | 重申 | → 购买 |
| 04/20/2023 | 455.56% | HC Wainwright & Co. | → 24 美元 | 启动覆盖范围开启 | → 购买 |
| 2022 年 12 月 12 日 | — | Cowen & Co. | 启动覆盖范围开启 | → 跑赢大盘 | |
| 2022 年 12 月 12 日 | 293.52% | 杰富瑞集团 | → 17 美元 | 启动覆盖范围开启 | → 购买 |
| 2022 年 12 月 12 日 | 478.7% | 派珀·桑德勒 | → 25 美元 | 启动覆盖范围开启 | → 超重 |
What is the target price for Acrivon Therapeutics (ACRV)?
Acrivon Therapeutics（ACRV）的目标价格是多少？
The latest price target for Acrivon Therapeutics (NASDAQ: ACRV) was reported by BMO Capital on November 10, 2023. The analyst firm set a price target for $24.00 expecting ACRV to rise to within 12 months (a possible 455.56% upside). 12 analyst firms have reported ratings in the last year.
BMO Capital于2023年11月10日公布了Acrivon Therapeutics（纳斯达克股票代码：ACRV）的最新目标股价。该分析公司将目标股价定为24.00美元，预计ACRV将在12个月内升至12个月内（可能上涨455.56％）。去年有12家分析公司公布了评级。
What is the most recent analyst rating for Acrivon Therapeutics (ACRV)?
分析师对Acrivon Therapeutics（ACRV）的最新评级是多少？
The latest analyst rating for Acrivon Therapeutics (NASDAQ: ACRV) was provided by BMO Capital, and Acrivon Therapeutics maintained their outperform rating.
BMO Capital对Acrivon Therapeutics（纳斯达克股票代码：ACRV）的最新分析师评级由BMO Capital提供，Acrivon Therapeutics维持跑赢大盘的评级。
When is the next analyst rating going to be posted or updated for Acrivon Therapeutics (ACRV)?
Acrivon Therapeutics（ACRV）的下一次分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Acrivon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Acrivon Therapeutics was filed on November 10, 2023 so you should expect the next rating to be made available sometime around November 10, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Acrivon Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Acrivon Therapeutics的最新评级是在2023年11月10日公布的，因此您应该预计下一个评级将在2024年11月10日左右公布。
Is the Analyst Rating Acrivon Therapeutics (ACRV) correct?
分析师对Acrivon Therapeutics（ACRV）的评级是否正确？
While ratings are subjective and will change, the latest Acrivon Therapeutics (ACRV) rating was a maintained with a price target of $25.00 to $24.00. The current price Acrivon Therapeutics (ACRV) is trading at is $4.32, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Acrivon Therapeutics（ACRV）评级保持不变，目标股价为25美元至24.00美元。Acrivon Therapeutics（ACRV）目前的交易价格为4.32美元，超出了分析师的预期区间。